Abdera Therapeutics Competitors and Similar CompaniesClear all
Abdera Therapeutics's competitors and similar companies include ImmunityBio, Cullinan Oncology, Sonnet BioTherapeutics and MABION.
 Abdera Therapeutics Abdera Therapeutics is a biopharmaceutical company that provides an antibody engineering platform to design and develop precision radiopharmaceuticals for cancer. |  ImmunityBio ImmunityBio (formerly known as NantKwest) is a clinical-stage immunotherapy company focused on harnessing the power of the immune system using natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. |  Cullinan Oncology Cullinan Oncology is a company that develops cancer treatments and a portfolio of oncology therapeutics. |  Sonnet BioTherapeutics Sonnet BioTherapeutics (formerly known as Chanticleer Holdings) is an oncology-focused biotechnology company. |  MABION Mabion is a biotechnology company engaged in research and development of biotechnology and biosimilar drugs to treat cancer, autoimmune, and metabolic diseases. | |
Founding Date | Founding Date 2020 | Founding Date 2014 | Founding Date 2016 | Founding Date 2011 | Founding Date 2007 |
Type | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Menlo Park, US HQ Vancouver, CA | Locations Culver City, US HQ San Diego, US Woburn, US | Locations Cambridge, US HQ | Locations Princeton, US HQ | Locations Konstantynów Łódzki, PL HQ |
Employees | Employees 723% increase | Employees 16116% increase | Employees 11131% increase | Employees 12 | Employees 95 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 4.3 b | Valuation ($) 981 m | Valuation ($) 2.9 m | Valuation ($) 21.7 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $113.3m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $1m (FY, 2025) | Revenue (est.) zł15.8m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $753k (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods zł24.1m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $112.5m (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit (zł7.2m) (FY, 2025) |
Net income | Net income N/A | Net income ($351.5m) (FY, 2025) | Net income ($219.9m) (FY, 2025) | Net income ($16m) (FY, 2025) | Net income (zł62.6m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 147.9m | Total funding raised N/A | Total funding raised $ 248.5m | Total funding raised $ 750k | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
ImmunityBio
HQ
Culver City, US
Employees
161↑ 16% increase
ImmunityBio (formerly known as NantKwest) is a clinical-stage immunotherapy company focused on harnessing the power of the immune system using natural killer cells to treat cancer, infectious diseases, and inflammatory diseases.
View companyCullinan Oncology
HQ
Cambridge, US
Employees
111↑ 31% increase
Cullinan Oncology is a company that develops cancer treatments and a portfolio of oncology therapeutics.
View companySonnet BioTherapeutics
HQ
Princeton, US
Employees
12
Sonnet BioTherapeutics (formerly known as Chanticleer Holdings) is an oncology-focused biotechnology company.
View companyMABION
HQ
Konstantynów Łódzki, PL
Employees
95
Mabion is a biotechnology company engaged in research and development of biotechnology and biosimilar drugs to treat cancer, autoimmune, and metabolic diseases.
View company